
Sign up to save your podcasts
Or
Clinical research treating mental illness with psychedelics has been ongoing for decades, but now there's a group of companies exclusively focused on using LSD and other psychedelics to treat mental health disorders.
Dan digs into the argument for legalizing prescription psychedelics, and the treacherous FDA approval path, with MindMed CEO JR Rahn, whose company recently listed on the Nasdaq.
4.3
689689 ratings
Clinical research treating mental illness with psychedelics has been ongoing for decades, but now there's a group of companies exclusively focused on using LSD and other psychedelics to treat mental health disorders.
Dan digs into the argument for legalizing prescription psychedelics, and the treacherous FDA approval path, with MindMed CEO JR Rahn, whose company recently listed on the Nasdaq.
3,902 Listeners
4,283 Listeners
8,680 Listeners
32,291 Listeners
1,529 Listeners
662 Listeners
111,917 Listeners
2,321 Listeners
6,866 Listeners
2,022 Listeners
5,462 Listeners
15,335 Listeners
4,367 Listeners
8,721 Listeners
10,613 Listeners
1,471 Listeners
459 Listeners